Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer

Update Il y a 5 ans
Reference: NCT01649271

Woman and Man

  • | Country :
  • France
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The aim of the study is to determine the Maximum Tolerated Dose (MTD) of afatinib in combination with 3-weekly trastuzumab in HER2 overexpressing cancer and to assess the efficacy of afatinib given at the MTD dosage, with 3-weekly trastuzumab in HER2 overexpressing metastatic breast cancer.


Inclusion criteria

  • Breast Neoplasms ,Stomach Neoplasms

Links